Artelo Biosciences, Inc. (NASDAQ:ARTL) Sees Significant Decline in Short Interest

Posted by Casey Walker on Oct 3rd, 2026

Artelo Biosciences, Inc. (NASDAQ:ARTL – Get Free Report) saw a significant decline in short interest in the month of September. As of September 15th, there was short interest totaling 22,550 shares, a decline of 37.2% from the August 31st total of 35,918 shares. Currently, 4.3% of the company’s shares are short sold. Based on an average daily volume of 45,211 shares, the short-interest ratio is presently 0.5 days.

Artelo Biosciences Trading Down 3.9%

ARTL stock opened at $3.68 on Friday. The firm has a market cap of $2.02 million, a PE ratio of -0.02 and a beta of -0.07. The stock has a 50-day moving average price of $5.90 and a 200-day moving average price of $19.66. Artelo Biosciences has a 1-year low of $3.45 and a 1-year high of $179.19.

Artelo Biosciences (NASDAQ:ARTL – Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported ($0.89) EPS for the quarter, beating the consensus estimate of ($6.48) by $5.59.

Analysts Set New Price Targets

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Artelo Biosciences in a report on Monday, September 21st. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Artelo Biosciences presently has a consensus rating of “Reduce”.

Get Our Latest Stock Analysis on ARTL

About Artelo Biosciences

(Get Free Report)

Artelo Biosciences, Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that target the endocannabinoid system, a network of receptors and signaling pathways involved in processes such as pain, inflammation, appetite and immune response. The company is headquartered in San Diego, California, and its research and development activities are directed toward pharmaceutical applications of cannabinoid biology rather than consumer cannabis products.

Artelo’s pipeline has included ART27.13, a peripherally restricted cannabinoid receptor agonist being evaluated for conditions associated with appetite loss and cancer-related cachexia.